Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

256 articles about Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)

• Cellectar Biosciences Announces Successful Conjugation Of Multiple Pierre Fabre Cytotoxic Compounds To PDC Delivery Platform; Initiates In Vivo Studies For Solid Tumors

  11/17/2016

• Cellectar Biosciences Announces INC Research As The CRO For The Phase II Trial Of CLR 131 In Hematologic Malignancies; $2 Million NCI Grant Covers Half Of Study Cost, With Potential Option To Pursue Additional $3 Million For Pivotal Trial

  11/15/2016

• Cellectar Biosciences Announces Recent Key Accomplishments And Third Quarter 2016 Financial Results

  11/11/2016

• Cellectar Biosciences To Host Conference Call On November 11 To Report Third Quarter 2016 Financial Results And Corporate Performance

  11/7/2016

• Cellectar Biosciences Announces Design For NCI-Supported Phase II Study Of CLR 131 In Multiple Myeloma And Other Hematologic Malignancies

  10/31/2016

• Cellectar Biosciences To Present At BIO Investor Forum

  10/13/2016

• Cellectar Biosciences To Present At SeeThru Equity And Dawson James Investor Conferences

  10/11/2016

• Cellectar Biosciences Announces Enrollment Of First Patient Into Third Cohort Of Its Phase I Clinical Study Of CLR 131 In Multiple Myeloma

  10/6/2016

• Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance For CLR 1603

  10/4/2016

• Cellectar Biosciences Announces New Positive Data From Phase I Clinical Study Of CLR 131 In Multiple Myeloma

  9/29/2016

• Cellectar Biosciences To Present At OktoberINVESTfest

  9/21/2016

• Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head And Neck Cancer In $12 Million University of Wisconsin SPORE Grant

  9/12/2016

• Cellectar Biosciences To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

  9/6/2016

• Cellectar Biosciences To Host Conference Call On August 15 To Report Second Quarter 2016 Financial Results And Corporate Performance

  8/8/2016

• Cellectar Biosciences Announces $2 Million NCI SBIR Contract For A Phase II Clinical Study

  8/3/2016

• Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President Of Corporate Development And Operations

  7/20/2016

• Cellectar Biosciences Announces Results Of NCI-Sponsored Study Of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer

  6/23/2016

• Cellectar Biosciences Announces Positive Data From Phase I Therapeutic Trial Of CLR 131 In Multiple Myeloma

  1/5/2016

• Cellectar Biosciences And Pierre Fabre Announce Oncology Research Collaboration

  12/16/2015

• Cellectar Biosciences To Provide Update On Phase I Multiple Myeloma Study

  12/9/2015